<code id='3E85DAF89C'></code><style id='3E85DAF89C'></style>
    • <acronym id='3E85DAF89C'></acronym>
      <center id='3E85DAF89C'><center id='3E85DAF89C'><tfoot id='3E85DAF89C'></tfoot></center><abbr id='3E85DAF89C'><dir id='3E85DAF89C'><tfoot id='3E85DAF89C'></tfoot><noframes id='3E85DAF89C'>

    • <optgroup id='3E85DAF89C'><strike id='3E85DAF89C'><sup id='3E85DAF89C'></sup></strike><code id='3E85DAF89C'></code></optgroup>
        1. <b id='3E85DAF89C'><label id='3E85DAF89C'><select id='3E85DAF89C'><dt id='3E85DAF89C'><span id='3E85DAF89C'></span></dt></select></label></b><u id='3E85DAF89C'></u>
          <i id='3E85DAF89C'><strike id='3E85DAF89C'><tt id='3E85DAF89C'><pre id='3E85DAF89C'></pre></tt></strike></i>

          fashion

          fashion

          author:leisure time    Page View:1499
          Monica Bertagnolli -- health policy coverage from STAT
          NIH Director Monica Bertagnolli Kevin Dietsch/Getty Images

          WASHINGTON — President Biden has promised to require fair prices from drugmakers that use federally funded research — and now, in a major recent move, said he’ll trigger government “march-in” on patents for drugs that run afoul of that goal.

          “It’s a simple principle. You shouldn’t pay the highest price in the world for drugs that your tax dollars have already helped create,” Biden said last month as he touted the move at the National Institutes of Health.

          advertisement

          But the new NIH director, locked in the center of this debate, isn’t taking any big steps yet.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health
          Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

          John-ArneRøttingenistheheadoftheWellcomeTrust,oneoftheworld’stopprivatefundersofbiomedicalresearch.I

          read more
          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more

          ALS patient reclaims some autonomy thanks to wearable 'robot'

          AlexHogan/STATJohnGoodsonpracticedmedicineforalmost50yearsatMassachusettsGeneralHospitalinBoston.Asa